Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VRCA
stocks logo

VRCA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
4.63M
+1246.9%
-1.080
-55%
6.10M
+77.38%
-0.580
-42%
7.00M
-44.89%
-0.410
-2150%
Estimates Revision
The market is revising Upward the revenue expectations for Verrica Pharmaceuticals Inc. (VRCA) for FY2025, with the revenue forecasts being adjusted by 1.6% over the past three months. During the same period, the stock price has changed by 64.94%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.6%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+49.45%
In Past 3 Month
Stock Price
Go Up
up Image
+64.94%
In Past 3 Month
Wall Street analysts forecast VRCA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRCA is 19.00 USD with a low forecast of 19.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast VRCA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRCA is 19.00 USD with a low forecast of 19.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.420
sliders
Low
19.00
Averages
19.00
High
19.00
Current: 8.420
sliders
Low
19.00
Averages
19.00
High
19.00
Lucid Capital
NULL -> Buy
initiated
$19
2025-11-05
Reason
Lucid Capital
Price Target
$19
2025-11-05
initiated
NULL -> Buy
Reason
Lucid Capital initiated coverage of Verrica Pharmaceuticals with a Buy rating and $19 price target. The firm views Verrica as a "de-risked" dermatology platform transitioning to a scalable growth model with expanding global leverage and strong capital efficiency. The company's Ycanth holds a first-mover advantage as the only in-office FDA-approved therapy for molluscum contagiosum, a large, underpenetrated pediatric market with broad payer coverage, the analyst tells investors in a research note.
Needham
Serge Belanger
Hold
Reiterates
n/a
2025-04-09
Reason
Needham
Serge Belanger
Price Target
n/a
2025-04-09
Reiterates
Hold
Reason
HC Wainwright & Co.
Oren Livnat
Hold
Reiterates
n/a
2025-04-08
Reason
HC Wainwright & Co.
Oren Livnat
Price Target
n/a
2025-04-08
Reiterates
Hold
Reason
Needham
Serge Belanger
Hold
Reiterates
n/a
2025-03-12
Reason
Needham
Serge Belanger
Price Target
n/a
2025-03-12
Reiterates
Hold
Reason
Needham
Serge Belanger
Hold
Reiterates
n/a
2024-12-20
Reason
Needham
Serge Belanger
Price Target
n/a
2024-12-20
Reiterates
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Verrica Pharmaceuticals Inc (VRCA.O) is -3.55, compared to its 5-year average forward P/E of -4.25. For a more detailed relative valuation and DCF analysis to assess Verrica Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.25
Current PE
-3.55
Overvalued PE
-1.79
Undervalued PE
-6.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.97
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.26
Undervalued EV/EBITDA
-5.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
32.21
Current PS
0.00
Overvalued PS
70.57
Undervalued PS
-6.16
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

VRCA News & Events

Events Timeline

(ET)
2025-11-24
08:06:47
Verrica Pharmaceuticals reveals $50M private placement funding initiative.
select
2025-11-14 (ET)
2025-11-14
16:07:06
Verrica Pharmaceuticals announces Q3 adjusted EPS of 13 cents, falling short of consensus estimate of 84 cents.
select
2025-11-10 (ET)
2025-11-10
08:13:23
Verrica Pharmaceuticals unveils new findings on VP-315 from Phase 2 study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-28Benzinga
Heartbeam Shares Surge Approximately 43%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Heartbeam Inc's Stock Surge: Heartbeam Inc's shares rose 43.3% in pre-market trading after announcing its regulatory strategy following the FDA's Not Substantially Equivalent decision on its Electrocardiogram Synthesis Software, with plans for an appeal or 510(k) resubmission.

  • Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including SMX PLC (+73.1%), Zenta Group (+26.7%), and Waton Financial (+21.1%), reflecting a positive trend in the market.

  • Major Losers: FBS Global Ltd experienced a sharp decline of 24.3%, while Tilray Brands fell 15% after announcing a reverse stock split, indicating volatility among certain stocks.

  • Market Overview: The pre-market trading session showed mixed results, with notable gains for some companies and significant losses for others, highlighting the fluctuating nature of the stock market.

[object Object]
Preview
2.0
11-26NASDAQ.COM
Biotech and Healthcare Stocks Top After-Hours Gainers: ICU, CGTX, MESO, VRCA, AHCO

  • Biotech Gains in After-Hours Trading: Several small- and mid-cap biotech and healthcare companies saw significant gains in after-hours trading, driven by corporate updates and financing developments.

  • SeaStar Medical's Leadership Change: SeaStar Medical's stock rose nearly 10% after the appointment of Michael Messinger as Chief Financial Officer, boosting investor confidence despite no new news.

  • Cognition Therapeutics' Speculative Buying: Cognition Therapeutics rebounded almost 11% in after-hours trading, likely due to speculative buying interest, following a decline during regular trading hours.

  • Mesoblast's Revenue Projection: Mesoblast's shares increased after management projected over $30 million in gross revenue for the December quarter, indicating strong demand for its cell therapy product, Ryoncil.

[object Object]
Preview
9.0
10-21Newsfilter
Verrica Pharmaceuticals Gains Favorable Response from EMA, Paving the Way for YCANTH® Approval in the EU

  • EMA Approval for YCANTH: The European Medicines Agency (EMA) has concluded that previous Phase 3 studies for YCANTH are sufficient for a Marketing Authorization Application (MAA) in the EU, with no additional studies required.

  • Verrica's Regulatory Submission Plans: Verrica Pharmaceuticals plans to initiate activities for the MAA filing, which could occur as early as Q4 2026, to address the significant unmet need for molluscum contagiosum treatment in Europe.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Verrica Pharmaceuticals Inc (VRCA) stock price today?

The current price of VRCA is 8.42 USD — it has increased 12.57 % in the last trading day.

arrow icon

What is Verrica Pharmaceuticals Inc (VRCA)'s business?

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).

arrow icon

What is the price predicton of VRCA Stock?

Wall Street analysts forecast VRCA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRCA is 19.00 USD with a low forecast of 19.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Verrica Pharmaceuticals Inc (VRCA)'s revenue for the last quarter?

Verrica Pharmaceuticals Inc revenue for the last quarter amounts to 14.34M USD, decreased -905.39 % YoY.

arrow icon

What is Verrica Pharmaceuticals Inc (VRCA)'s earnings per share (EPS) for the last quarter?

Verrica Pharmaceuticals Inc. EPS for the last quarter amounts to -0.03 USD, decreased -99.39 % YoY.

arrow icon

What changes have occurred in the market's expectations for Verrica Pharmaceuticals Inc (VRCA)'s fundamentals?

The market is revising Upward the revenue expectations for Verrica Pharmaceuticals Inc. (VRCA) for FY2025, with the revenue forecasts being adjusted by 1.6% over the past three months. During the same period, the stock price has changed by 64.94%.
arrow icon

How many employees does Verrica Pharmaceuticals Inc (VRCA). have?

Verrica Pharmaceuticals Inc (VRCA) has 71 emplpoyees as of December 05 2025.

arrow icon

What is Verrica Pharmaceuticals Inc (VRCA) market cap?

Today VRCA has the market capitalization of 79.81M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free